In­dus­try calls for changes in two REMS guid­ances

In­dus­try groups rep­re­sent­ing the phar­ma­ceu­ti­cal, biotech­nol­o­gy and gener­ic drug in­dus­tries are call­ing for changes to two re­cent FDA draft guid­ances on REMS.

The

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER